Company to Take Part in Fireside Chat Wednesday, January 18, 2023 at 7:00am PST / 10:00am EST SUNNYVALE, Calif. , Jan. 10, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the B. Riley Securities' 3rd Annual Oncology Conference taking place January
SUNNYVALE, Calif. , Nov. 28, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that its commitment to delivering better, faster cancer treatment technology and superior service is resulting in highly satisfied customers. According to the IMV ServiceTrak™ Radiation Oncology
Hospital Adds Accuray ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony ® Technologies to Both Radixact Systems, Creating the Ultimate System for Personalized Cancer Care SUNNYVALE, Calif. , Nov. 16, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Oscar Lambret
Strong customer demand. Navigating FX and Supply Chain Challenges. Company reiterates full year guidance. SUNNYVALE, Calif. , Nov. 2, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2023 ended September 30, 2022 .
SUNNYVALE, Calif. , Nov. 1, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo ® C radiation therapy system for the Type B market has been submitted to the Chinese National Medical Products Administration
SUNNYVALE, Calif. , Oct. 26, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved reimbursement for the CyberKnife ® System for the treatment of trigeminal neuralgia (TN).
Collaboration places emphasis on personalized medicine; brings together key precision diagnostic and treatment delivery tools aimed at creating shorter, more comfortable and more effective treatments for patients CHICAGO and SUNNYVALE, Calif. , Oct. 21, 2022 /PRNewswire/ -- GE Healthcare and
SUNNYVALE, Calif. , Oct. 19, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2023, ended September 30, 2022, after the market close on November 2, 2022. Management will host a conference call to review the results at 1:30
SUNNYVALE, Calif. , Oct. 13, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company, in partnership with C-RAD AB (NASDAQ Stockholm: CRAD B), will showcase an important new option for improving the care of people diagnosed with breast cancer during the 2022 ASTRO (
Latest research published in The Lancet Oncology : suggests bladder side effects were experienced half as often with CyberKnife SBRT as with conventional linear accelerator delivered SBRT two years after treatment Almost 20 years of global clinical data: shows the non-surgical CyberKnife platform
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.
